Lyu Nenan, Wang Yinuo, Wang Jianhua, Zhang Zhenyu, Kong Weimin
Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
Department of Gynecologic Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
J Cancer Res Ther. 2018 Jun;14(Supplement):S444-S449. doi: 10.4103/0973-1482.181178.
To investigate the value of peripheral blood plasma levels of septin-9 and clusterin protein in the diagnosis of epithelial ovarian cancer (EOC).
The peripheral blood plasma samples were obtained from 137 EOC patients, 12 borderline ovarian tumor patients, 10 benign ovarian tumor patients, 41 benign pelvic lesion patients, and 58 healthy women. The peripheral plasma septin-9 and clusterin proteins levels were measured by enzyme-linked immunosorbent assay. The power of test was evaluated with the area under the receiver operating characteristic curve (ROC) (AUC).
The mean levels of plasma septin-9 and clusterin in EOC patients were significantly higher than that in healthy women (P = 0.002, P = 0.021). The mean levels of plasma septin-9 in benign pelvic lesion patients were significantly higher than that in healthy women (P = 0.007). The mean levels of plasma septin-9 in epithelial ovarian carcinoma patients with tumor family history or distant metastases were significantly higher than that of patients without (P = 0.040, P = 0.025). The AUC of septin-9 protein was 0.712, when the optimal cut-off point was 0.28, the sensitivity and diagnostic specificity were 82.5% and 50.0%, respectively; the AUC of clusterin was 0.636, and when the optimal cut-off point was 87.96 ng/ml, the sensitivity and diagnostic specificity was 71.5% and 41.4%, respectively.
The plasma levels of septin-9 and clusterin in ovarian cancer patients were abnormally elevated, which might be used as potential candidates of peripheral blood tumor biomarkers for early diagnosis of EOC and septin-9 might be related to distal metastases of EOC. The septin-9 might play the promotion role, which protein level relates to not only the distal metastases but also the prognosis of EOC. Due to the limit of sample volume, further enlargement of the sample size and set up of the follow-up system is in need to in-depth study the relationship between plasma protein concentration with the distal metastases, and further explore its correlation with the prognosis of EOC.
探讨外周血中septin-9和簇集蛋白水平在上皮性卵巢癌（EOC）诊断中的价值。
采集137例EOC患者、12例卵巢交界性肿瘤患者、10例良性卵巢肿瘤患者、41例良性盆腔病变患者及58例健康女性的外周血血浆样本。采用酶联免疫吸附测定法检测外周血浆中septin-9和簇集蛋白水平。通过受试者工作特征曲线（ROC）下面积（AUC）评估检测效能。
EOC患者血浆septin-9和簇集蛋白的平均水平显著高于健康女性（P = 0.002，P = 0.021）。良性盆腔病变患者血浆septin-9的平均水平显著高于健康女性（P = 0.007）。有肿瘤家族史或远处转移的上皮性卵巢癌患者血浆septin-9的平均水平显著高于无上述情况的患者（P = 0.040，P = 0.025）。septin-9蛋白的AUC为0.712，最佳截断点为0.28时，灵敏度和诊断特异性分别为82.5%和50.0%；簇集蛋白的AUC为0.636，最佳截断点为87.96 ng/ml时，灵敏度和诊断特异性分别为71.5%和41.4%。
卵巢癌患者血浆septin-9和簇集蛋白水平异常升高，可能作为EOC早期诊断的外周血肿瘤生物标志物的潜在候选物，且septin-9可能与EOC的远处转移有关。septin-9可能起促进作用，其蛋白水平不仅与远处转移有关，还与EOC的预后有关。由于样本量有限，需要进一步扩大样本量并建立随访系统，以深入研究血浆蛋白浓度与远处转移的关系，并进一步探索其与EOC预后的相关性。
